moneyheap
TNDM +14.05% today · Analysis updated Nov 13, 2026, 1:21 PM ET
Why is Tandem Diabetes Care, Inc. (TNDM) stock up today?
Tandem Diabetes Care received FDA 510(k) clearance for its Tandem Mobi pump to operate as a tubeless automated insulin delivery system with up to seven days of wear, sending shares surging 14% to $19.97 on Nov 13. The clearance unlocks a major commercial catalyst, allowing Mobi to directly challenge tubeless competitors such as Insulet while giving existing Mobi users flexibility between tubed and tubeless wear without replacing pump hardware. Commercial availability in the U.S. is scheduled for the first half of 2027 through pharmacy channels, which currently cover roughly 50% of insured U.S. lives. This positive regulatory milestone comes immediately following solid Q3 results ($283.7M revenue, beat by $17.8M) and as incoming CEO Jeannette Bankes takes the helm on Nov 16.
News behind the analysis
- Tandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of WearTandem Diabetes Care received FDA 510(k) clearance for a tubeless Tandem Mobi cartridge and infusion set worn for up to seven days, with a commercial launch planned for the first half of 2027.
- Tandem Diabetes stock jumps on FDA clearance for tubeless pumpShares rallied sharply following regulatory clearance for Mobi's tubeless automated insulin delivery system, expanding its commercial reach against competitors.
- Tandem Diabetes Care wins FDA clearance for tubeless Mobi set worn up to 7 daysExisting Mobi pumps will support the new tubeless consumables through pharmacy benefit channels covering roughly 50% of insured U.S. lives.
- Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up - Time to Buy?MarketBeat reviews Tandem's post-earnings recovery and analyst price targets after beating Q3 expectations with sales reaching $283.69 million.
- Tandem Diabetes Care Reports Third Quarter 2026 Financial ResultsTandem reported worldwide sales of $283.7 million, narrowing its net loss to $7.1 million and generating $18.0 million in adjusted EBITDA while reaffirming full-year guidance.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care is a San Diego company that makes insulin pumps for people with diabetes, mainly the t:slim X2 and the smaller Tandem Mobi. Its main selling point is Control-IQ+ software, which works with continuous glucose monitors from Dexcom and Abbott to adjust insulin doses automatically.
How it makes money
Tandem makes money by selling insulin pumps and the disposable supplies they use, such as cartridges and infusion sets, which customers keep buying over time. About two-thirds of sales come from the US and the rest from other countries. The company expects 2026 sales of roughly $1.07–1.09 billion. It is also moving US customers to a pay-as-you-go model through pharmacies, which spreads payments out over time.
What usually moves TNDM
- Pump shipments and growth in supply sales
- Competition from tubeless pumps such as Insulet's Omnipod
- Insurance coverage and the shift to pay-as-you-go pharmacy billing
- New product approvals, such as tubeless Mobi and use for type 2 diabetes
- Gross margin and progress toward profitability